The Food and Drug Administration and the Federal Trade Commission announced this week that they had sent warning letters to three companies that advertised its cannabidiol products as curing or alleviating symptoms of certain diseases.

“This is the first time the FTC has joined in on a warning letter,” said Neil Willner, an associate in the cannabis group at Wilson Elser Moskowitz Edelman & Dicker in White Plains, New York.